Cargando…

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

BACKGROUND: Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). OBJECTIVE: To define the treatment target for SpA including ankylosing spondyliti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, Braun, Jürgen, Dougados, Maxime, Emery, Paul, FitzGerald, Oliver, Helliwell, Philip, Kavanaugh, Arthur, Kvien, Tore K, Landewé, Robert, Luger, Thomas, Mease, Philip, Olivieri, Ignazio, Reveille, John, Ritchlin, Christopher, Rudwaleit, Martin, Schoels, Monika, Sieper, Joachim, de Wit, Martinus, Baraliakos, Xenofon, Betteridge, Neil, Burgos-Vargas, Ruben, Collantes-Estevez, Eduardo, Deodhar, Atul, Elewaut, Dirk, Gossec, Laure, Jongkees, Merryn, Maccarone, Mara, Redlich, Kurt, van den Bosch, Filip, Wei, James Cheng-Chung, Winthrop, Kevin, van der Heijde, Désirée
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Recommendation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888616/ https://www.ncbi.nlm.nih.gov/pubmed/23749611 http://dx.doi.org/10.1136/annrheumdis-2013-203419

Ejemplares similares

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis
por: Schoels, M M, et al.
Publicado: (2014)

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
por: Smolen, Josef S, et al.
Publicado: (2018)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?
por: van Lunteren, Miranda, et al.
Publicado: (2019)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists
por: Gossec, L, et al.
Publicado: (2008)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
por: Dougados, Maxime, et al.
Publicado: (2012)

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
por: Rahman, Proton, et al.
Publicado: (2021)

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
por: Gladman, Dafna D., et al.
Publicado: (2022)

Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis: Results of an International Survey
por: van der Heijde, Désirée, et al.
Publicado: (2014)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort
por: van Lunteren, Miranda, et al.
Publicado: (2018)

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
por: van der Heijde, D., et al.
Publicado: (2017)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
por: Baraliakos, Xenofon, et al.
Publicado: (2023)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
por: Marzo-Ortega, Helena, et al.
Publicado: (2020)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
por: Kavanaugh, Arthur, et al.
Publicado: (2016)

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
por: Mease, Philip J., et al.
Publicado: (2023)

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis
por: Baraliakos, X, et al.
Publicado: (2005)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
por: Mease, Philip J., et al.
Publicado: (2019)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
por: Braun, J, et al.
Publicado: (2011)

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain
por: Deodhar, Atul, et al.
Publicado: (2016)

Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts
por: Ez-Zaitouni, Zineb, et al.
Publicado: (2017)

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_23h0kvekcan0qqemkol56sn37n